Pfizer, BioNTech Announce Omicron Vaccine Clinical Trial

Pfizer and BioNTech announced this morning that they began a clinical trial for their Omicron-specific Covid-19 vaccine candidate. The study will evaluate the vaccine for safety, tolerability and the level of immune response as both a primary series and a booster dose in 1,420 adults ages 18 to 55. Participants will be broken into three groups. The first group will receive two doses of the current vaccine at least 90 to 180 days before the study. They will receive one or two doses of the Omicron-specific vaccine. The second group of participants received three doses of the current vaccine at least 90 to 180 days prior to the study and will receive one dose of the current Covid-19 vaccine or the Omicron-specific vaccine. The final group of participants have not received any Covid-19 vaccine and will receive three doses of the Omicron-specific vaccine.